ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates
Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026 Strategic financial restructuring strengthens balance sheet, extending expected cash runway into 2029 Abstracts accepted for presentation at ASH 2026, highlighting...